Henry Schein
HSIC
$84.84
-0.24%
Henry Schein Inc. is a global healthcare solutions company that distributes dental and medical supplies, equipment, and value-added services to office-based practitioners and alternative care sites, operating through Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. As one of the largest distributors in the dental and medical markets, the company occupies a critical middleman position in the healthcare supply chain, with deep customer relationships and a broad product catalog that create meaningful scale advantages. The current investor narrative centers on the company's ability to sustain mid-single-digit revenue growth while navigating margin pressure from a mix shift toward lower-margin distribution and technology offerings, alongside a notable slowdown in its technology segment. Recent quarterly results show revenue growth of 6.3% year-over-year, but net income has been volatile and free cash flow turned negative in the most recent quarter, raising questions about working capital management and the sustainability of its capital return program. Analysts remain cautiously optimistic, with a consensus buy rating but a wide target range that reflects uncertainty around the company's growth trajectory and profitability improvement.…
HSIC
Henry Schein
$84.84
Investment Opinion: Should I buy HSIC Today?
The synthesized recommendation for Henry Schein is a Hold. The core thesis is that the company's steady revenue growth and improving gross margins are offset by negative free cash flow and thin net margins, creating an uncertain near-term outlook. The analyst consensus is a buy with an average target of $98.19, implying 15.7% upside, but the wide target range ($64-$112) and mixed ratings suggest limited conviction. A Hold rating reflects the balance between potential upside if earnings rebound and the risks if they do not.
Supporting evidence for the Hold includes: 1) Revenue grew 6.31% YoY in Q1 2026 to $3.368 billion, showing resilience; 2) Gross margin improved to 31.77% from 29.61%, indicating better pricing or mix; 3) The forward PE of 14.14x is attractive if EPS reaches $6.975, but the trailing PE of 23.14x is near historical highs; 4) Free cash flow turned negative at -$136 million in Q1 2026, a significant concern; and 5) The PS ratio of 0.70x is low, but the PEG ratio of 3.23x suggests overvaluation relative to growth. Without industry average data, we note that medical distributors typically trade at a discount to the broader healthcare sector.
The biggest risks that could invalidate the thesis are: 1) A failure to achieve the projected EPS rebound, which would make the forward PE misleading; 2) Continued negative free cash flow leading to balance sheet stress; and 3) Competitive pressures eroding margins in the core distribution business. The rating would upgrade to Buy if free cash flow turns sustainably positive and EPS growth accelerates, or downgrade to Sell if revenue growth decelerates below 5% or margins contract further. Relative to its history and peers, HSIC appears fairly valued, with the market pricing in a recovery that is not yet confirmed.
Sign up to view all
HSIC 12-Month Price Forecast
Henry Schein presents a balanced risk-reward profile. The company's steady revenue growth and improving gross margins are positives, but negative free cash flow and thin net margins are significant concerns. The valuation is mixed: the forward PE of 14.14x is attractive if earnings materialize, but the PEG ratio of 3.23x suggests overvaluation relative to growth. Analyst sentiment is moderately bullish, but the wide target range and mixed ratings reflect limited conviction. I would upgrade to bullish if free cash flow turns sustainably positive and EPS growth accelerates, and downgrade to bearish if revenue growth decelerates below 5% or margins contract further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Henry Schein's 12-month outlook, with a consensus price target around $98.19 and implied upside of +15.7% versus the current price.
Average Target
$98.19
0 analysts
Implied Upside
+15.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$64 - $112
Analyst target range
Henry Schein is covered by 16 analysts, with a consensus recommendation of "buy" and an average target price of $98.19. This average target implies an upside of approximately 15.7% from the current price of $84.84. The recommendation mean of 2.29 (on a scale where 1 is strong buy and 5 is strong sell) suggests a moderately bullish sentiment, but the distribution of ratings includes several neutral and underweight calls, indicating that not all analysts are convinced. The consensus leans bullish, but the presence of underweight ratings from firms like Morgan Stanley suggests a divergence in views.
The target price range is wide, from a low of $64.00 to a high of $112.00, representing a spread of 75% relative to the low target. The high target of $112 would require a 32% increase from current levels and likely assumes successful execution on margin improvement, technology segment growth, and multiple expansion. The low target of $64, which is 24.6% below the current price, likely prices in a recession, continued margin compression, or competitive pressures. Recent institutional ratings show a mix of actions: BTIG upgraded to Buy in June 2026, while Morgan Stanley maintained an Underweight rating in April 2026, and UBS and Mizuho remained Neutral. The wide target spread and mixed ratings indicate high uncertainty and limited conviction among analysts, which could lead to increased volatility around earnings announcements.
Bulls vs Bears: HSIC Investment Factors
The bull case for Henry Schein rests on its consistent revenue growth, improving gross margins, and a forward PE of 14.1x that suggests significant earnings growth ahead. Analysts are moderately bullish with a consensus buy rating and a $98.19 average target, implying 15.7% upside. However, the bear case is equally compelling: negative free cash flow, thin net margins of 3.18%, high debt-to-equity of 1.14, and a PEG ratio of 3.23 all point to financial fragility. The most important tension is whether the company can deliver the dramatic earnings rebound implied by the forward PE—if it fails, the stock could re-rate sharply lower. Currently, the bear evidence appears slightly stronger given the negative FCF and margin volatility, but the low beta and analyst support provide a cushion.
Bullish
- Analyst consensus buy with 15.7% upside: 16 analysts rate HSIC a buy (recommendation mean 2.29) with an average target price of $98.19, implying 15.7% upside from the current $84.84. The high target of $112 suggests 32% upside if margin improvement and technology growth materialize.
- Forward PE of 14.1x signals value: The forward PE of 14.14x is well below the trailing PE of 23.14x, implying the market expects EPS to rise to $6.975 in the coming year from $0.93 in Q1 2026. If this earnings rebound occurs, the stock is undervalued relative to its historical PE range of 15x-26x.
- Steady revenue growth and margin expansion: Q1 2026 revenue grew 6.31% YoY to $3.368 billion, continuing a pattern of consistent top-line expansion. Gross margin improved to 31.77% from 29.61% a year earlier, indicating better product mix or pricing power.
- Low beta and strong relative performance: HSIC's beta of 0.812 means it is about 19% less volatile than the market, appealing to risk-averse investors. Over the past year, the stock gained 23.76% versus the S&P 500's 15.01%, outperforming by 8.75 percentage points.
Bearish
- Negative free cash flow raises red flags: Free cash flow turned negative at -$136 million in Q1 2026, a sharp reversal from +$338 million in Q4 2025, due to a $278 million working capital outflow. This raises concerns about the sustainability of capital returns and internal funding.
- Thin net margins leave little room for error: Net margin was only 3.18% in Q1 2026, and operating margin was 5.40%. Over the past four quarters, net income fluctuated between $86 million and $107 million, showing no clear trend of margin expansion.
- High debt-to-equity and weak quick ratio: The debt-to-equity ratio of 1.14 is relatively high, and the quick ratio of 0.75 indicates heavy reliance on inventory to meet short-term obligations. This could strain liquidity if demand slows.
- PEG ratio of 3.23 suggests overvaluation: The PEG ratio of 3.23x is well above 1, indicating the stock is expensive relative to its expected earnings growth. This suggests the market may be pricing in overly optimistic growth expectations.
HSIC Technical Analysis
Henry Schein's stock has been in a sustained uptrend over the past year, with a 1-year price change of +23.76%, significantly outpacing the S&P 500's +15.01% gain. The current price of $84.84 sits at approximately 75.6% of its 52-week range, calculated as ($84.84 - $61.95) / ($92.18 - $61.95), indicating the stock is in the upper half of its annual range but not at its highs. This positioning suggests the stock retains positive momentum but has room to run before hitting overbought territory, though the recent pullback from the 52-week high of $92.18 warrants attention. The stock's beta of 0.812 implies it is roughly 19% less volatile than the broader market, which may appeal to risk-averse investors but could also mean it lags in strong bull markets.
Short-term momentum has turned negative, with a 1-month price change of -4.98% contrasting sharply with the 3-month gain of +6.16% and the 6-month gain of +17.36%. This divergence suggests a temporary pullback within a longer-term uptrend, as the 1-month decline of nearly 5% has erased some of the recent gains but has not broken the 3-month or 6-month positive trends. The relative strength versus the S&P 500 over the past month is -4.02%, meaning the stock has underperformed the index by that margin, while over the past year it has outperformed by 8.75%. The recent weakness may be attributed to profit-taking after a strong run or concerns about the upcoming earnings, but without volume data or RSI, it is difficult to gauge the intensity of selling pressure.
Key technical support lies near the 52-week low of $61.95, which represents a 27% decline from current levels and would likely require a significant deterioration in fundamentals to breach. Resistance is established at the 52-week high of $92.18, about 8.7% above the current price; a breakout above this level would signal renewed bullish momentum and potentially open the door to new highs. The stock's max drawdown of -17.23% over the past year indicates it has experienced a moderate correction, and with a beta of 0.812, investors can expect lower volatility than the market, but the recent 1-month decline of 4.98% shows it is not immune to pullbacks. A breakdown below the $80 level could test the 200-day moving average, while a move above $92 would confirm the uptrend's continuation.
Beta
0.81
0.81x market volatility
Max Drawdown
-17.2%
Largest decline past year
52-Week Range
$62-$92
Price range past year
Annual Return
+23.8%
Cumulative gain past year
| Period | HSIC Return | S&P 500 |
|---|---|---|
| 1m | -5.0% | -0.5% |
| 3m | +6.2% | +2.3% |
| 6m | +17.4% | +16.6% |
| 1y | +23.8% | +14.8% |
| ytd | +10.4% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HSIC Fundamental Analysis
Henry Schein's revenue trajectory shows steady growth, with the most recent quarter (Q1 2026) reporting revenue of $3.368 billion, a 6.31% increase year-over-year from $3.168 billion in Q1 2025. This follows a pattern of consistent top-line expansion, with Q4 2025 revenue at $3.437 billion, Q3 2025 at $3.339 billion, and Q2 2025 at $3.24 billion, indicating that growth is not accelerating but remains resilient. The revenue mix is heavily weighted toward Healthcare Distribution, which generated $2.953 billion, or 87.7% of total revenue, while Technology contributed only $221 million, or 6.6%, highlighting the company's dependence on the distribution business. The technology segment's small size and potential for higher margins could be a future growth driver, but currently, the company's growth is largely tied to the slower-growing distribution business.
Profitability remains thin, with a net income of $107 million in Q1 2026, translating to a net margin of 3.18%, which is typical for a distribution company but leaves little room for error. The gross margin for Q1 2026 was 31.77%, up from 29.61% in Q1 2025, indicating some improvement in product mix or pricing power, but the operating margin was only 5.40%, reflecting high operating expenses. Over the past four quarters, net income has fluctuated between $86 million and $107 million, with net margins ranging from 2.65% to 3.18%, showing no clear trend of margin expansion. The company's ROE of 12.27% is respectable for the sector, but the low net margin means that any revenue decline or cost increase could quickly erode profitability.
The balance sheet shows a debt-to-equity ratio of 1.14, which is relatively high and indicates that the company relies on debt financing to fund its operations and growth. The current ratio of 1.38 suggests adequate short-term liquidity, but the quick ratio of 0.75 from historical data indicates that inventory makes up a significant portion of current assets, which could be a risk if demand slows. Free cash flow turned negative in Q1 2026 at -$136 million, a sharp reversal from positive $338 million in Q4 2025, due to a large working capital outflow of $278 million, primarily from an increase in accounts receivable and other working capital items. The TTM free cash flow is $431 million, but the volatility and negative quarterly FCF raise concerns about the company's ability to internally fund its growth and share repurchases without increasing debt.
Quarterly Revenue
$3.4B
2026-03
Revenue YoY Growth
+6.3%
YoY Comparison
Gross Margin
31.8%
Latest Quarter
Free Cash Flow
$431000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HSIC Overvalued?
Since Henry Schein reported positive net income of $107 million in the most recent quarter, the PE ratio is the appropriate primary valuation metric. The trailing PE ratio is 23.14x, while the forward PE is 14.14x, implying that the market expects significant earnings growth in the coming year. This large gap between trailing and forward PE suggests that analysts anticipate EPS to rise substantially, likely from $0.93 in Q1 2026 to an estimated average of $6.975 for the full year, which would represent a dramatic increase. However, such a sharp earnings rebound may be optimistic given the company's recent margin pressures and negative free cash flow.
Compared to the industry average, Henry Schein's valuation appears mixed. The PS ratio of 0.70x is notably low, but this is typical for a distribution company with high revenue and low margins. The EV/EBITDA of 12.65x is moderate, and the PB ratio of 2.83x is in line with historical levels. Without specific industry average data provided, we can infer from the sector that medical distribution companies often trade at a discount to the broader healthcare sector due to lower margins and growth prospects. The forward PE of 14.14x is below the trailing PE, which could indicate a value opportunity if earnings materialize, but the PEG ratio of 3.23x suggests the stock is overvalued relative to its expected growth rate.
Historically, Henry Schein's PE ratio has ranged from around 15x to 26x over the past few years, with the current trailing PE of 23.14x near the upper end of that range. The PS ratio of 0.70x is significantly lower than historical levels, which have been above 2.0x in previous years, but this is due to the recent decline in the stock price and the company's revenue growth. The current valuation appears to be pricing in a recovery in earnings, as evidenced by the low forward PE, but if the company fails to deliver on growth expectations, the stock could be vulnerable to a re-rating. The dividend yield is 0%, so total return depends entirely on price appreciation.
PE
23.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 15x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Henry Schein faces significant financial and operational risks. The company's debt-to-equity ratio of 1.14 is elevated, and its quick ratio of 0.75 indicates that inventory comprises a large portion of current assets, leaving little cushion if demand slows. Free cash flow turned negative at -$136 million in Q1 2026 due to a $278 million working capital outflow, primarily from rising accounts receivable, which raises questions about the sustainability of its capital return program. Additionally, net margins are razor-thin at 3.18%, and net income has been volatile, ranging from $86 million to $107 million over the past four quarters, leaving little room for error if costs rise or revenue declines.
Market and competitive risks are also pronounced. The stock trades at a trailing PE of 23.14x, near the upper end of its historical range of 15x-26x, and a PEG ratio of 3.23 suggests it is overvalued relative to expected growth. With a beta of 0.812, HSIC is less volatile than the market, but this also means it may lag in strong bull markets. The wide analyst target range of $64 to $112 reflects high uncertainty, and recent mixed ratings—including an Underweight from Morgan Stanley—highlight divergent views. The company's heavy reliance on the distribution segment (87.7% of revenue) exposes it to competitive pressures and potential margin compression from online distributors and direct-to-consumer models.
The worst-case scenario would involve a continued deterioration in working capital, leading to further negative free cash flow and a potential dividend cut (though the yield is currently 0%). If the anticipated earnings rebound fails to materialize, the stock could re-rate toward its 52-week low of $61.95, representing a 27% decline from the current price of $84.84. The analyst low target of $64 implies a 24.6% downside, and a broader market correction could exacerbate the decline given the stock's recent negative momentum. In this adverse scenario, investors could lose 25-30% from current levels, with the $64 target serving as a realistic bear-case floor.
FAQ
The key risks for HSIC are ranked as follows: 1) Financial risk: Negative free cash flow of -$136 million in Q1 2026 and a debt-to-equity ratio of 1.14 could strain liquidity if working capital does not improve. 2) Operational risk: Thin net margins of 3.18% leave little room for error, and revenue is heavily concentrated in the distribution segment (87.7% of total). 3) Market risk: The stock's PEG ratio of 3.23x suggests overvaluation, and a beta of 0.812 means it may lag in bull markets but also decline less in downturns. 4) Competitive risk: The distribution business faces pressure from online competitors and potential margin compression. These risks could lead to a re-rating toward the 52-week low of $61.95, a 27% decline.
The 12-month forecast for HSIC includes three scenarios: Bull case (25% probability) targets $98-$112, assuming successful margin improvement and positive free cash flow; Base case (55% probability) targets $85-$98, assuming steady growth and gradual margin recovery; Bear case (20% probability) targets $64-$75, assuming continued negative free cash flow and earnings misses. The base case is most likely, with the key assumption that revenue grows 5-6% and free cash flow turns positive. The analyst average target of $98.19 aligns with the base case, implying 15.7% upside from current levels.
HSIC's valuation is mixed. The trailing PE of 23.14x is near the upper end of its historical range of 15x-26x, suggesting the stock is not cheap on trailing earnings. However, the forward PE of 14.14x is attractive, implying the market expects EPS to rise to $6.975 from $0.93 in Q1 2026. The PS ratio of 0.70x is low for a healthcare distributor, but the PEG ratio of 3.23x indicates overvaluation relative to expected growth. Compared to peers, medical distributors often trade at a discount, so the current valuation may be fair if earnings materialize. The market is pricing in a significant earnings rebound, which may be optimistic given recent margin pressures.
From a risk/reward perspective, HSIC is a moderate buy for conservative investors. The stock trades at $84.84, with a consensus analyst target of $98.19 implying 15.7% upside, and a forward PE of 14.14x that suggests undervaluation if earnings meet expectations. However, the biggest downside risk is the negative free cash flow of -$136 million in Q1 2026, which could pressure the balance sheet and limit capital returns. The low beta of 0.812 makes it suitable for risk-averse investors, but the PEG ratio of 3.23x indicates the stock is not cheap relative to growth. It is a good buy for those with a long-term horizon who believe in the earnings recovery story, but near-term volatility is likely.
HSIC is more suitable for long-term investment due to its low beta (0.812), steady revenue growth, and lack of dividend, which means total return depends on price appreciation over time. The company is in a mature growth stage, and earnings visibility is moderate, with analyst estimates ranging widely. Short-term trading could be risky given the recent 4.98% one-month decline and negative momentum. A suggested minimum holding period is 2-3 years to allow for the earnings recovery and working capital improvements to materialize. Investors should monitor quarterly free cash flow and margin trends to reassess the thesis.